Nektar Therapeutics Payments of Debt Issuance Costs
Nektar Therapeutics (NKTR) reported Payments of Debt Issuance Costs of $4.50 million for the 12-month period ending 2012-12-31, per its 10-K filed 2015-02-26.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2015-02-26
- Nektar Therapeutics payments of debt issuance costs for the quarter ending 2012-12-31 was $100.00K.
- Nektar Therapeutics payments of debt issuance costs for fiscal 2012 was $4.50M.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 12 month |
|---|---|---|---|
| 2012-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | $4.50M 10-K · filed 2015-02-26 | |
| 2012-09-30 | $4.40M 10-Q · filed 2013-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |